Regulation of interferon and Toll‐like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms

X Hu, SD Chakravarty, LB Ivashkiv - Immunological reviews, 2008 - Wiley Online Library
Activated macrophages and their inflammatory products play a key role in innate immunity
and in pathogenesis of autoimmune/inflammatory diseases. Macrophage activation needs to …

Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs

SD Chakravarty, G Zhu, MC Tsai, VP Mohan… - Infection and …, 2008 - Am Soc Microbiol
Tumor necrosis factor (TNF) is a prototypic proinflammatory cytokine that contributes significantly
to the development of immunopathology in various disease states. A complication of …

Long‐term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin‐23, through two years: Results from a phase III …

…, SD Chakravarty, D van der Heijde… - Arthritis & …, 2022 - Wiley Online Library
Objective To assess long‐term efficacy and safety of guselkumab, an interleukin‐23 p19
subunit (IL‐23p19) inhibitor, in patients with active psoriatic arthritis (PsA) from the phase III …

Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER …

…, X Baraliakos, SD Chakravarty… - The Lancet …, 2021 - thelancet.com
Background Guselkumab was efficacious in reducing signs and symptoms of psoriatic arthritis
in the phase 3 DISCOVER-1 and DISCOVER-2 studies. We aimed to evaluate the efficacy …

Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two …

PS Helliwell, DD Gladman, SD Chakravarty, S Kafka… - RMD open, 2020 - rmdopen.bmj.com
Background The interleukin-12/23p40-subunit-inhibitor ustekinumab significantly improved
spondylitis-related symptoms through Week 24 in psoriatic arthritis (PsA) patients with …

[HTML][HTML] Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn's disease: an integrated analysis of phase II/III clinical development programs

…, LS Gensler, Z Yang, C Gasink, SD Chakravarty… - Drug safety, 2019 - Springer
Introduction Theoretical risks of biologic agents remain under study. Objective The aim of this
study was to integrate 1-year safety data from 12 ustekinumab registrational trials. Methods …

Efficacy and safety of guselkumab, an interleukin‐23p19–specific monoclonal antibody, through one year in biologic‐naive patients with psoriatic arthritis

…, EC Hsia, AP Kollmeier, SD Chakravarty… - Arthritis & …, 2021 - Wiley Online Library
Objective Guselkumab, a human monoclonal antibody specific to interleukin‐23p19,
demonstrated efficacy and safety versus placebo through week 24 of the phase III DISCOVER‐2 …

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis

…, S Peterson, A Schubert, SD Chakravarty… - …, 2021 - academic.oup.com
Objective The efficacy of the novel interleukin (IL)-23p19 inhibitor guselkumab for psoriatic
arthritis (PsA) has recently been demonstrated in two phase 3 trials (DISCOVER-1 & -2) but …

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III …

…, EC Hsia, AP Kollmeier, SD Chakravarty… - RMD open, 2021 - rmdopen.bmj.com
Objective Evaluation of the efficacy and safety of guselkumab, a human monoclonal antibody
targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) through 1 …

[HTML][HTML] Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double …

…, PJ Mease, P Bird, ER Soriano, SD Chakravarty… - Trials, 2022 - Springer
Background Axial involvement constitutes a specific domain of psoriatic arthritis (PsA). Interleukin
(IL)-23 inhibitors have demonstrated improvement in axial PsA (axPsA) symptoms, but …